Unnamed: 0,title,date,stock,sentiment
894567.0,Neogenomics Filing Shows Registration For $100M Common Stock Shelf Offering,2020-04-29 17:27:00-04:00,NEO,neutral
894568.0,"SVB Leerink Maintains Outperform on NeoGenomics, Raises Price Target to $35",2020-04-29 06:17:00-04:00,NEO,neutral
894569.0,"NeoGenomics Q1 EPS $(0.020) Misses $0.020 Estimate, Sales $106.030M Beat $104.580M Estimate",2020-04-28 07:19:00-04:00,NEO,negative
894570.0,"Stephens & Co. Reinstates Overweight on NeoGenomics, Announces $33 Price Target",2020-04-21 07:21:00-04:00,NEO,negative
894571.0,NeoGenomics Highlights Integration Of Indica Labs' HALO AP Image Analysis Platform,2020-04-03 07:04:00-04:00,NEO,neutral
894572.0,"Needham Maintains Buy on NeoGenomics, Raises Price Target to $33",2020-03-17 10:43:00-04:00,NEO,neutral
894573.0,"Craig-Hallum Reinstates Buy on NeoGenomics, Announces $38 Price Target",2020-03-02 10:45:00-05:00,NEO,neutral
894574.0,"Raymond James Maintains Outperform on NeoGenomics, Raises Price Target to $32",2020-03-02 07:20:00-05:00,NEO,neutral
894575.0,"Needham Maintains Buy on NeoGenomics, Raises Price Target to $32",2020-02-28 07:39:00-05:00,NEO,neutral
894576.0,"Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $30",2020-02-28 07:17:00-05:00,NEO,neutral
894577.0,First Analysis Upgrades NeoGenomics to Strong Buy,2020-02-28 06:00:00-05:00,NEO,positive
894578.0,"First Analysis Downgrades NeoGenomics to Outperform, Announces $35 Price Target",2020-01-23 07:08:00-05:00,NEO,neutral
894579.0,NeoGenomics Files Non-timely 10-Q,2019-11-13 07:54:00-05:00,NEO,neutral
894580.0,"NeoGenomics Q3 Adj. EPS $0.07 Beats $0.06 Estimate, Sales $104.672M Beat $99.1M Estimate",2019-10-29 07:45:00-04:00,NEO,neutral
894581.0,"Raymond James Maintains Outperform on NeoGenomics, Raises Price Target to $27",2019-07-31 07:57:00-04:00,NEO,neutral
894582.0,"NeoGenomics Q2 EPS $0.02 Misses $0.06 Estimate, Sales $101.713M Beat $97.3M Estimate",2019-07-30 07:48:00-04:00,NEO,negative
894583.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,NEO,positive
894584.0,NeoGenomics Reports New $250M Credit Deal,2019-06-27 16:01:00-04:00,NEO,positive
894585.0,NeoGenomics shares are trading lower after the company announced a common stock public offering of 7 million shares priced at $21.25 per share.,2019-05-22 09:29:00-04:00,NEO,positive
894586.0,NeoGenomics Shares Down 4% Premarket As Co. Late Tues. Priced 7M Shares At $21.25/Share,2019-05-22 08:20:00-04:00,NEO,positive
894587.0,NeoGenomics Reports Commencement Of $150M Common Stock Offering,2019-05-20 16:16:00-04:00,NEO,neutral
894588.0,"NeoGenomics Q1 EPS $0.07 Beats $0.04 Estimate, Sales $95.577M Beat $90.61M Estimate",2019-04-30 07:52:00-04:00,NEO,neutral
894589.0,NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ,2019-03-11 07:03:00-04:00,NEO,negative
894590.0,NeoGenomics Sees FY19 Sales $379M-$395M vs $385.69M Est.,2019-02-19 07:21:00-05:00,NEO,neutral
894591.0,"NeoGenomics Q4 EPS $0.06 Beats $0.05 Estimate, Sales $76.475M Beat $71.43M Estimate",2019-02-19 07:21:00-05:00,NEO,neutral
894592.0,NeoGenomics shares are trading higher after the company was added to the S&P SmallCap 600.,2019-01-09 10:37:00-05:00,NEO,positive
894593.0,"S&P Dow Jones Indices Announces 'NeoGenomics Set to Join S&P SmallCap 600,' Will Replace Engility",2019-01-08 17:29:00-05:00,NEO,positive
894594.0,"Needham Initiates Coverage On NeoGenomics with Buy Rating, Announces $14 Price Target",2019-01-03 08:23:00-05:00,NEO,neutral
894595.0,NeoGenomics Announces Pricing On Secondary Offering Of Common Stock By Selling Stockholder,2018-12-12 07:36:00-05:00,NEO,neutral
894596.0,NeoGenomics Reports ~10.84M Share Common Stock Offering By Selling Shareholder,2018-12-11 16:11:00-05:00,NEO,positive
894597.0,QIAGEN And NeoGenomics Announce Master Service Agreement,2018-11-30 16:05:00-05:00,NEO,positive
894598.0,"Stocks Which Set New 52-Week High Yesterday, October 31st",2018-11-01 10:33:00-04:00,NEO,neutral
894599.0,"Stocks Which Set New 52-Week High Yesterday, October 29th",2018-10-30 12:35:00-04:00,NEO,neutral
894600.0,"NeoGenomics Raises FY18 Adj. EPS Guidance From $0.12-$0.17 vs $0.17-$0.19 vs $0.15 Est., Narrows FY18 Sales Guidance From $260M-$272M to $270M-272M vs 268.13M",2018-10-30 07:18:00-04:00,NEO,neutral
894601.0,"NeoGenomics Q3 EPS $0.02, Inline, Sales $69.1M Beat $66.33M Estimate",2018-10-30 07:17:00-04:00,NEO,neutral
894602.0,"Stocks That Made New 52-Week Highs Friday, October 26th",2018-10-29 09:33:00-04:00,NEO,neutral
894603.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,NEO,neutral
894604.0,"Neonode Shares Halted For Volatility; Stock Has Been Halted Multiple Times Today, Turn On Benzinga Signals To Be Alerted To All Halts And Resumptions",2018-10-01 10:10:00-04:00,NEO,positive
894605.0,"Neonode Shares Resume Trade, Up 32.2%",2018-10-01 10:09:00-04:00,NEO,positive
894606.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,NEO,neutral
894607.0,"NeoGenomics Reports Winning Of Clinical Reference Laboratory Testing Services Deal With Premier, No Terms Disclosed",2018-09-12 08:17:00-04:00,NEO,positive
894608.0,"Leerink Swann Initiates Coverage On NeoGenomics with Outperform Rating, Announces $18 Price Target",2018-08-21 07:54:00-04:00,NEO,neutral
894609.0,NeoGenomics Late Thursday Announced 9.8M Share Common Stock Offering Will Be Priced At $12.75/Share,2018-08-10 08:36:00-04:00,NEO,positive
894610.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,NEO,neutral
894611.0,NeoGenomics shares trading down 7.2% after the company announced a $125M common stock offering.,2018-08-06 17:54:00-04:00,NEO,positive
894612.0,NeoGenomics Announces $125M Common Stock Offering,2018-08-06 16:19:00-04:00,NEO,neutral
894613.0,NeoGenomics Shares Down 18% After Co. Lowered FY18 EPS Outlook from $0.16-$0.20 To $0.12-$0.17,2018-07-24 09:00:00-04:00,NEO,positive
894614.0,NeoGenomics Sees FY18 Sales $260M-$272M vs $265.29M Est.,2018-07-24 07:22:00-04:00,NEO,neutral
894615.0,"NeoGenomics Q2 EPS $0.07 Beats $0.04 Estimate, Sales $67.746M Beat $66.18M Estimate",2018-07-24 07:21:00-04:00,NEO,neutral
894616.0,"Pharmaceutical Product Development, NeoGenomics Labs Report Formation Of Strategic Alliance To Provide Global Pathology, Molecular Testing Solution To PPD's Pharma, Biotech Clients",2018-06-01 08:08:00-04:00,NEO,positive
894617.0,First Analysis Downgrades NeoGenomics to Equal-Weight,2018-05-02 08:17:00-04:00,NEO,neutral
894618.0,"NeoGenomics Reaffirms FY18 Outlook Adj. EPS $0.15-$0.20 vs $0.17 Est., Sales $260M-$272M vs $263.9M Est.",2018-05-01 07:26:00-04:00,NEO,neutral
894619.0,"Neogenomics Reports Q1 Adj. EPS $0.04 Beats $0.03 Est., Sales $63.42B Beats $61.21B Est.",2018-05-01 07:24:00-04:00,NEO,neutral
894620.0,BTIG Research Upgrades NeoGenomics to Outperform,2018-04-16 07:00:00-04:00,NEO,neutral
894621.0,NeoGenomics Names George Cardoza President Of Pharma Services Division And Sharon Virag As CFO,2018-03-20 07:03:00-04:00,NEO,neutral
894622.0,"NeoGenomics Sees FY18 Adj. EPS $0.15-$0.20 vs $0.21 Est., Sales $260-$272M vs $281M Est.",2018-02-21 07:05:00-05:00,NEO,neutral
894623.0,"NeoGenomics Reports Q4 EPS $0.05 vs $0.04 Est., Sales $67.8M vs $66.2M Est.",2018-02-21 07:05:00-05:00,NEO,neutral
894624.0,"NeoGenomics Sees Q4 Adj. EPS $0.04 to $0.05 vs $0.04 Est., Sales $65M to $67M vs $67M Est.",2017-10-25 07:21:00-04:00,NEO,neutral
894625.0,"NeoGenomics Q3 Adj. EPS $0.01 vs $0.02 Est., Sales $63.1M vs $63.9M Est.",2017-10-25 07:20:00-04:00,NEO,neutral
894626.0,"NeoGenomics Sees Q4 Sales $65M-$67M vs $69.1M Est., Adj. EBITDA $9M-$10M",2017-10-12 16:04:00-04:00,NEO,neutral
894627.0,"NeoGenomics Reports Prelim. Q3 Results: Sales ~$63.1M vs $65.9M Est., Adj. EBITDA ~$6M",2017-10-12 16:02:00-04:00,NEO,neutral
894628.0,"NeoGenomics Offers Update On Impact From Hurricane Irma: 'had minimal impacts to its Fort Myers, FL facility'",2017-09-11 15:09:00-04:00,NEO,neutral
894629.0,BTIG Research Downgrades NeoGenomics to Neutral,2017-09-11 07:12:00-04:00,NEO,neutral
894630.0,Gabelli & Co. Initiates Coverage On NeoGenomics with Buy Rating,2017-08-24 05:55:00-04:00,NEO,neutral
894631.0,NeoGenomics Reiterates FY 2017 Guidance,2017-07-25 07:09:00-04:00,NEO,neutral
894632.0,"NeoGenomics Q2 EPS $0.04 vs $0.03 Est., Sales $66.1M vs $63.0M Est",2017-07-25 07:09:00-04:00,NEO,neutral
894633.0,NeoGenomics Announces Results Of New Clinical Trial Demonstrating Sensitivity Of NeoLAB Liquid Biopsy Prostatetest Was 97% In PRedicting Presence Of High Grade Prostate Cancer While Conventional Biopsies in This Study Was 78%,2017-05-15 08:54:00-04:00,NEO,negative
894634.0,NeoGenomics and Definiens Enter Agreement to Develop Novel Assays for Clinical Trials,2017-03-13 07:08:00-04:00,NEO,positive
894635.0,"NeoGenomics Sees FY17 Adj. EPS $0.17-$0.22 vs $0.21 Est., Sales $260M-$275M vs $274M Est.",2017-02-22 07:08:00-05:00,NEO,neutral
894636.0,"NeoGenomics Reports Q4 Adj. EPS $0.05 vs $0.03 Est., Sales $60.5M vs $61.8M Est.",2017-02-22 07:07:00-05:00,NEO,neutral
894637.0,Amended 13D Filing from GE on NeoGenomics Shows 25.4% Stake,2016-12-27 17:09:00-05:00,NEO,neutral
894638.0,"Cantor Fitzgerald Initiates Coverage On NeoGenomics at Overweight, Announces $11.00 Target",2016-12-15 08:05:00-05:00,NEO,negative
894639.0,"First Analysis Initiates Coverage on NeoGenomics at Overweight, Announces $11.00 PT",2016-10-04 04:03:00-04:00,NEO,negative
894640.0,Raymond James Initiates Coverage on NeoGenomics at Outperform,2016-09-09 03:49:00-04:00,NEO,neutral
894641.0,BTIG Research Downgrades NeoGenomics to Neutral,2016-07-27 06:23:00-04:00,NEO,neutral
894642.0,"Roth Capital Assumes NeoGenomics at Buy, Announces $10.00 PT",2016-05-11 04:09:00-04:00,NEO,neutral
894643.0,"Benchmark Initiates Coverage on NeoGenomics at Buy, Announces $8.00 PT",2016-03-11 07:43:00-05:00,NEO,neutral
894644.0,NeoGenomics Announces Amended Strategic Alliance Agreement with Covance Central Laboratory Services,2015-10-28 20:31:00-04:00,NEO,positive
894645.0,"BTIG Research Initiates Coverage on NeoGenomics at Buy, Announces $7.00 PT",2015-06-23 09:07:00-04:00,NEO,neutral
894646.0,"BTIG Research Initiates Coverage on NeoGenomics at Buy, Announces $7.00 PT",2015-06-22 16:52:00-04:00,NEO,neutral
894647.0,NeoGenomics Launches Molecular Test for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia ,2014-10-23 07:06:00-04:00,NEO,negative
894648.0,Neogenomics Sees Q3 EPS $(0.01)-0.01 vs $0.01 Est; Sees Sales $22.0M-23.50M vs $20.02M Est,2014-07-17 07:07:00-04:00,NEO,neutral
894649.0,"Neogenomics Reports Q2 EPS of $0.01, Inline",2014-07-17 07:07:00-04:00,NEO,neutral
894650.0,"Neogenomics Raises Q2 Sales Guidance from $18.80M-19.30M to $20.0M-20.50M vs $18.90M Est, Affirms EPS Outlook",2014-06-23 08:06:00-04:00,NEO,neutral
894651.0,"Roth Capital Initiates Coverage on Neogenomics at Buy, Announces $6.00 PT",2014-05-12 06:42:00-04:00,NEO,neutral
894652.0,"Longbow Research Initiates Coverage on Neogenomics at Buy, Announces $6.00 PT",2014-05-12 06:10:00-04:00,NEO,neutral
894653.0,Neogenomics Sees FY2014 EPS $0.03-0.05 vs $0.01 Est; Sees Sales $73.0M-77.0M vs $71.91M Est,2014-04-23 07:11:00-04:00,NEO,neutral
894654.0,Neogenomics Sees Q2 EPS $0.00-0.01 vs $(0.01) Est; Sees Sales $18.80M-19.30M vs $17.68M Est,2014-04-23 07:10:00-04:00,NEO,neutral
894655.0,"Neogenomics Reports Q1 EPS of $0.00, Inline; Revenue of $18.20M vs $17.68M Est",2014-04-23 07:09:00-04:00,NEO,neutral
894656.0,NeoGenomics Launches Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome ,2014-03-18 07:06:00-04:00,NEO,negative
894657.0,Neogenomics Sees FY2014 EPS $0.05-0.07 vs $0.07 Est; Sees Sales $73.0M-77.0M vs $72.81M Est,2014-02-19 07:10:00-05:00,NEO,neutral
894658.0,Neogenomics Sees Q1 EPS $0.01-0.02 vs $0.01 Est,2014-02-19 07:10:00-05:00,NEO,neutral
894659.0,"Neogenomics Reports Q4 EPS of $0.02, Inline; Revenue of $18.32M vs $17.80M Est",2014-02-19 07:09:00-05:00,NEO,neutral
894660.0,"Stephens & Co. Initiates Coverage on Neogenomics at Overweight, Announces $6.00 PT",2014-02-14 08:36:00-05:00,NEO,negative
894661.0,William Blair Initiates Coverage on Neogenomics at Outperform,2014-01-08 08:57:00-05:00,NEO,neutral
894662.0,NeoGenomics Launches New Test for Detection of Mutations in Calreticulin Gene,2014-01-07 07:15:00-05:00,NEO,neutral
894663.0,Covance NeoGenomics Enter Strategic Alliance for Anatomic Pathology and Specialty Laboratory Testing Services,2013-11-18 07:09:00-05:00,NEO,neutral
894664.0,Neogenomics Lowers FY2013 EPS Guidance from $0.03-0.05 to $0.01-0.04 vs $0.04 Est; Lowers FY2013 Sales Guidance from $68.0M-73.0M to $63.0M-66.0M vs $69.50M Est,2013-07-31 07:49:00-04:00,NEO,negative
894665.0,Neogenomics Sees Q3 EPS $0.00-0.01 vs $0.01 Est; Sees Sales $15.80M-16.40M,2013-07-31 07:48:00-04:00,NEO,neutral
894666.0,Neogenomics Reports Q2 EPS of $0.01 vs $0.00 Est; Revenue of $15.60M vs $16.20M Est,2013-07-31 07:07:00-04:00,NEO,neutral
894667.0,"Ladenburg Thalmann Downgrades Neogenomics to Neutral, Removes $3.75 PT",2013-04-25 14:28:00-04:00,NEO,neutral
894668.0,Neogenomics Sees FY2013 EPS $0.03-0.05 vs $0.06 Est; Sees Sales $68.0M-73.0M vs $70.51M Est,2013-02-14 07:29:00-05:00,NEO,neutral
894669.0,Neogenomics Sees Q1 EPS $0.00-0.01 vs $0.01 Est,2013-02-14 07:29:00-05:00,NEO,neutral
894670.0,Neogenomics Reports Q4 EPS of $0.00 vs $(0.01) Est; Revenue of $14.90M vs $14.88M Est,2013-02-14 07:29:00-05:00,NEO,neutral
894671.0,Neogenomics Files $25M Mixed Securities Shelf,2013-01-17 12:23:00-05:00,NEO,positive
894672.0,NeoGenomics Launches NeoSITE Barrett's Esophagus FISH Test for Diagnosis of High Grade Dysplasia/Esophageal Cancer ,2012-12-17 07:11:00-05:00,NEO,negative
